• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Cosmos Health Inc.

    3/31/25 4:33:37 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    NT 10-K 1 cosm_nt10k.htm NT 10-K cosm_nt10k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C.

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

    SEC File Number: 000-54436

    CUSIP Number: 221413206

     

    (Check one:)  ☒ Form 10-K   ☐ Form 20-F   ☐ Form 11-K   ☐ Form 10-Q   ☐ Form 10-D    ☐ Form N-SAR   ☐ Form N-CSR

     

    For Period Ended: December 31, 2024

     

    ☐     Transition Report on Form 10-K

    ☐     Transition Report on Form 20-F

    ☐     Transition Report on Form 11-K

    ☐     Transition Report on Form 10-Q

    ☐     Transition Report on Form N-SAR

     

    For the Transition Period Ended: _________________

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  Not applicable

     

     

    PART I - REGISTRANT INFORMATION

     

    Full Name of Registrant: Cosmos Health Inc.

    Former Name if applicable: Cosmos Holdings, Inc.

    Address of Principal Executive Office: 5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece

     

     

     

      

    PART II - RULE 12B-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed: (Check box if appropriate)

     

    ☒

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, NCSR, or the transition report or portion thereof, could not be filed within the prescribed period.

     

    Cosmos Health Inc. (the “Company”) could not complete the filing of its Annual Report on Form 10-K for the period ended December 31, 2024 due to delays in obtaining and compiling information to be included in its Form 10-K, including, but not limited to, our XBRL filing, which delay could not be eliminated by the Company without unreasonable effort and expense.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification:

     

    Georgios Terzis (312) 536-5469

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding twelve months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s)

     

    ☒  Yes          ☐  No

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐  Yes          ☒  No

     

            If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

    2

     

      

    Cosmos Health Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    COSMOS HEALTH INC.

     

     

     

     

     

    Date:  March 31, 2025

    By:

    /s/ Georgios Terzis

     

     

    Georgios Terzis

     

     

    Chief Executive Officer

    Principal Executive Officer

     

     

     

    3

     

    Get the next $COSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

      S-1/A - Cosmos Health Inc. (0001474167) (Filer)

      6/3/25 5:07:47 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Cosmos Health Inc.

      10-Q - Cosmos Health Inc. (0001474167) (Filer)

      5/15/25 9:20:41 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Cosmos Health Inc. (0001474167) (Filer)

      5/7/25 1:30:41 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

      CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a

      5/15/25 2:30:35 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

      CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp

      5/7/25 2:30:10 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

      CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was not

      5/6/25 1:40:33 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care